Table 2.
Treatment and Stage-Specific Cumulative Rates (%) of Recurrence and Death, by Year, With 95% CIs
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|
| Recurrence | |||||
| All | |||||
| FU | 10.9 (9.8 to 12.0)* | 21.3 (19.9 to 22.7)* | 26.5 (24.9 to 28.0)* | 29.9 (28.3 to 31.5)* | 31.8 (30.2 to 33.4)* |
| FOLFOX | 7.5 (6.9 to 8.0)* | 17.6 (16.7 to 18.3)* | 22.2 (21.3 to 23.1)* | 24.5 (23.6 to 25.4)* | 26.3 (25.3 to 27.2)* |
| Stage II | |||||
| FU | 4.1 (2.7 to 5.4) | 9.5 (7.4 to 11.5)* | 12.2 (9.9 to 14.5)* | 13.9 (11.4 to 16.3)* | 15.3 (12.7 to 17.8)* |
| FOLFOX | 2.1 (1.4 to 2.9) | 5.8 (4.5 to 7.0)* | 8.2 (6.8 to 9.7)* | 9.4 (7.9 to 11.0)* | 10.3 (8.7 to 11.9)* |
| Stage III | |||||
| FU | 13.1 (11.8 to 14.5)* | 25.2 (23.5 to 27.0)* | 31.2 (29.3 to 33.1)* | 35.2 (33.2 to 37.1)* | 37.3 (35.3 to 39.2)* |
| FOLFOX | 8.5 (7.8 to 9.1)* | 19.8 (18.9 to 20.7)* | 24.9 (23.9 to 25.9)* | 27.5 (26.4 to 28.5)* | 29.4 (28.4 to 30.5)* |
| Death | |||||
| All | |||||
| FU | 2.9 (2.3 to 3.4) | 8.3 (7.3 to 9.2) | 13.6 (12.4 to 14.8) | 18.5 (17.1 to 19.8) | 22.3 (20.8 to 23.7)* |
| FOLFOX | 2.7 (2.3 to 3.0) | 7.3 (6.8 to 7.9) | 11.8 (11.2 to 12.5) | 16.4 (15.6 to 17.2) | 20.0 (19.1 to 20.8)* |
| Stage II | |||||
| FU | 1.3 (0.5 to 2.0) | 3.8 (2.5 to 5.1) | 5.5 (3.9 to 7.0) | 8.3 (6.3 to 10.2) | 10.2 (8.1 to 12.3) |
| FOLFOX | 1.5 (0.9 to 2.2) | 3.4 (2.4 to 4.3) | 5.7 (4.4 to 6.9) | 7.6 (6.2 to 9.0) | 9.4 (7.8 to 10.9) |
| Stage III | |||||
| FU | 3.4 (2.7 to 4.1) | 9.7 (8.5 to 10.9) | 16.3 (14.8 to 17.8)* | 21.8 (20.2 to 23.5)* | 26.3 (24.5 to 28.0)* |
| FOLFOX | 2.9 (2.5 to 3.3) | 8.1 (7.5 to 8.7) | 13.0 (12.2 to 13.8)* | 18.2 (17.3 to 19.0)* | 22.1 (21.1 to 23.0)* |
Abbreviations: FOLFOX, infusional fluorouracil, leucovorin, oxaliplatin; FU, fluorouracil.
*
Indicates significant difference, where the 95% CIs do not overlap